Inflammatory and neuroendocrine biomarkers of prognosis after ischemic stroke

Expert Review of Neurotherapeutics

Volumn 11, Issue 2, 2011, Pages 225-239

  Katan, Mira ^a   Elkind, Mitchell Sv ^a,b  

^a Columbia University ^*  (United States)

^b NONE   (United States)

Author keywords

Inflammatory markers; Ischemic stroke; Neuroendocrine markers; Outcome; Prognostic biomarker; Risk stratification

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CATECHOLAMINE; COPEPTIN; D DIMER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; GELATINASE B; HYDROCORTISONE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 6; INTERLEUKIN 8; L SELECTIN; PADGEM PROTEIN; PLASMIN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

BRAIN INJURY; BRAIN ISCHEMIA; HEMOSTASIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; OUTCOME ASSESSMENT; PROGNOSIS; REVIEW;

BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; HUMANS; INFLAMMATION; NEUROSECRETORY SYSTEMS; PROGNOSIS; STROKE; TREATMENT OUTCOME;

EID: 79951604546     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.200     Document Type: Review

References (201)

1. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart Disease and Stroke Statistics - 2010 Update: a report from the American Heart Association. Circulation 121(7), e46-e215 (2010).
2. Maas MB, Furie KL. Molecular biomarkers in stroke diagnosis and prognosis. Biomark. Med. 3(4), 363-383 (2009).
3. NIH-FDA Conference: Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications. Abstracts. Dis. Markers 14(4), 187-334 (1998).
4. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22(9), 391-397 (1999). (Pubitemid 29453643)
5. Chamorro A, Urra X, Planas AM. Infection after acute ischemic stroke: a manifestation of brain-induced immunodepression. Stroke 38(3), 1097-1103 (2007). (Pubitemid 46568484)
6. Shoja MM, Tubbs RS, Shokouhi G, Loukas M, Ghabili K, Ansarin K. The potential role of carbon dioxide in the neuroimmunoendocrine changes following cerebral ischemia. Life Sci. 83(11-12), 381-387 (2008).
7. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron 67(2), 181-198 (2010).
8. DeVries AC, Joh HD, Bernard O et al. Social stress exacerbates stroke outcome by suppressing Bcl-2 expression. Proc. Natl Acad. Sci. USA 98(20), 11824-11828 (2001). (Pubitemid 32928813)
9. El Husseini N, Laskowitz DT. Clinical application of blood biomarkers in cerebrovascular disease. Expert Rev. Neurother. 10(2), 189-203 (2010).
10. Stamova B, Xu H, Jickling G et al. Gene expression profiling of blood for the prediction of ischemic stroke. Stroke 41(10), 2171-2177 (2010).
11. Tang Y, Xu H, Du X et al. Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J. Cereb. Blood Flow Metab. 26(8), 1089-1102 (2006). (Pubitemid 44134079)
12. Laterza OF, Modur VR, Crimmins DL et al. Identification of novel brain biomarkers. Clin. Chem. 52(9), 1713-121 (2006). (Pubitemid 44330705)
13. Xu H, Tang Y, Liu DZ et al. Gene expression in peripheral blood differs after cardioembolic compared with large-vessel atherosclerotic stroke: biomarkers for the etiology of ischemic stroke. J. Cereb. Blood Flow Metab. 28(7), 1320-1328 (2008). (Pubitemid 351896646)
14. Dave JR, Williams AJ, Yao C, Lu XC, Tortella FC. Modeling cerebral ischemia in neuroproteomics. Methods Mol. Biol. 566, 25-40 (2009).
15. Allard L, Burkhard PR, Lescuyer P et al. PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin. Chem. 51(11), 2043-2051 (2005). (Pubitemid 41532619)
16. Cuadrado E, Rosell A, Penalba A et al. Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study. J. Proteome Res. 8(6), 3191-3197 (2009).
17. Koizumi S, Yamamoto S, Hayasaka T et al. Imaging mass spectrometry revealed the production of lyso-phosphatidylcholine in the injured ischemic rat brain. Neuroscience 168(1), 219-225 (2010).
18. Endres M, Engelhardt B, Koistinaho J et al. Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc. Dis. 25(3), 268-278 (2008). (Pubitemid 351450431)
19. Priller J, Flugel A, Wehner T et al. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat. Med. 7(12), 1356-1361 (2001).
20. Eglitis MA, Mezey E. Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc. Natl Acad. Sci. USA 94(8), 4080-4085 (1997). (Pubitemid 27180502)
21. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl Acad. Sci. USA 96(23), 13496-13500 (1999).
22. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat. Rev. Immunol. 5(8), 629-640 (2005). (Pubitemid 41113194)
23. Emsley HC, Smith CJ, Georgiou RF et al. A randomised Phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry 76(10), 1366-1372 (2005). (Pubitemid 41360973)
24. Kerschensteiner M, Gallmeier E, Behrens L et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J. Exp. Med. 189(5), 865-870 (1999). (Pubitemid 29189691)
25. Emsley HC, Smith CJ, Tyrrell PJ, Hopkins SJ. Inflammation in acute ischemic stroke and its relevance to stroke critical care. Neurocrit. Care 9(1), 125-138 (2008).
26. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron 67(2), 181-198 (2010).
27. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J. Neuroimmunol. 184(1-2), 53-68 (2007). (Pubitemid 46365991)
28. Shohami E, Ginis I, Hallenbeck JM. Dual role of tumor necrosis factor a in brain injury. Cytokine Growth Factor Rev. 10(2), 119-130 (1999). (Pubitemid 29446376)
29. Protopsaltis J, Kokkoris S, Korantzopoulos P et al. Prediction of long-term functional outcome in patients with acute ischemic non-embolic stroke. Atherosclerosis 203(1), 228-235 (2009).
30. Hopkins SJ. The pathophysiological role of cytokines. Leg. Med. (Tokyo) 5(Suppl. 1), S45-S57 (2003). (Pubitemid 36537830)
31. Castellanos M, Sobrino T, Pedraza S et al. High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke. Neurology 71(23), 1862-1868 (2008).
32. Smith CJ, Emsley HC, Gavin CM et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. 4, 2 (2004).
33. Vila N, Castillo J, Davalos A, Esteve A, Planas AM, Chamorro A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke 34(3), 671-675 (2003). (Pubitemid 36307391)
34. Waje-Andreassen U, Krakenes J, Ulvestad E et al. IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol. Scand. 111(6), 360-365 (2005). (Pubitemid 40705305)
35. Sotgiu S, Zanda B, Marchetti B et al. Inflammatory biomarkers in blood of patients with acute brain ischemia. Eur. J. Neurol. 13(5), 505-513 (2006). (Pubitemid 43823367)
36. Basic Kes V, Simundic AM, Nikolac N, Topic E, Demarin V. Pro-inflammatory and anti-inflammatory cytokines in acuteischemic stroke and their relation to early neurological deficit and stroke outcome. Clin. Biochem. 41(16-17), 1330-1334 (2008).
37. Blanco M, Castellanos M, Rodriguez-Yanez M et al. High blood pressure and inflammation are associated with poor prognosis in lacunar infarctions. Cerebrovasc. Dis. 22(2-3), 123-129 (2006). (Pubitemid 44114453)
38. Rallidis LS, Vikelis M, Panagiotakos DB et al. Inflammatory markers and in-hospital mortality in acute ischaemic stroke. Atherosclerosis 189(1), 193-197 (2006). (Pubitemid 44441281)
39. Whiteley W, Jackson C, Lewis S et al. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med. 6(9), e1000145 (2009).
40. Emsley HC, Smith CJ, Tyrrell PJ, Hopkins SJ. Inflammation in acute ischemic stroke and its relevance to stroke critical care. Neurocrit. Care 9(1), 125-138 (2008).
41. Castillo J, Alvarez-Sabin J, Martinez-Vila E, Montaner J, Sobrino T, Vivancos J. Inflammation markers and prediction of post-stroke vascular disease recurrence: the MITICO study. J. Neurol. 256(2), 217-224 (2009).
42. Whiteley W, Jackson C, Lewis S et al. Association of circulating inflammatory markers with recurrent vascular events after stroke. A prospective cohort study. Stroke DOI: 10.1161/strokeaha.110.588954 (2010) (Epub ahead of print.)
43. Welsh P, Lowe G, Chalmers J et al. Associations of proinflammatory cytokines with the risk of recurrent stroke. Stroke 39(8), 2226-2230 (2008).
44. Liu T, Clark RK, McDonnell PC et al. Tumor necrosis factor-a expression in ischemic neurons. Stroke 25(7), 1481-1488 (1994). (Pubitemid 24198599)
45. Murakami Y, Saito K, Hara A et al. Increases in tumor necrosis factor-a following transient global cerebral ischemia do not contribute to neuron death in mouse hippocampus. J. Neurochem. 93(6), 1616-1622 (2005). (Pubitemid 40853285)
46. Castellanos M, Leira R, Serena J et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 35(7), 1671-1676 (2004). (Pubitemid 38823645)
47. Rosell A, Alvarez-Sabin J, Arenillas JF et al. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 36(7), 1415-1420 (2005). (Pubitemid 40967504)
48. Castellanos M, Castillo J, Garcia MM et al. Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke 33(4), 982-987 (2002). (Pubitemid 34293579)
49. Licata G, Tuttolomondo A, Di Raimondo D, Corrao S, Di Sciacca R, Pinto A. Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. Thromb. Haemost. 101(5), 929-937 (2009).
50. Elkind MS, Cheng J, Boden-Albala B et al. Tumor necrosis factor receptor levels are associated with carotid atherosclerosis. Stroke 33(1), 31-37 (2002). (Pubitemid 34052180)
51. Blann AD, McCollum CN. Increased levels of soluble tumor necrosis factor receptors in atherosclerosis: no clear relationship with levels of tumor necrosis factor. Inflammation 22(5), 483-491 (1998). (Pubitemid 28498042)
52. Valgimigli M, Ceconi C, Malagutti P et al. Tumor necrosis factor-a receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine- Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation 111(7), 863-870 (2005). (Pubitemid 40279887)
53. Blann AD, Ridker PM, Lip GY. Inflammation, cell adhesion molecules, and stroke: tools in pathophysiology and epidemiology? Stroke 33(9), 2141-2143 (2002). (Pubitemid 35014611)
54. Boos CJ, Lip GY, Blann AD. Circulating endothelial cells in cardiovascular disease. J. Am. Coll. Cardiol. 48(8), 1538-1547 (2006). (Pubitemid 44550075)
55. Nadar SK, Lip GY, Lee KW, Blann AD. Circulating endothelial cells in acute ischaemic stroke. Thromb. Haemost. 94(4), 707-712 (2005). (Pubitemid 41489228)
56. Makin AJ, Blann AD, Chung NA, Silverman SH, Lip GY. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. Eur. Heart J. 25(5), 371-376 (2004). (Pubitemid 38391518)
57. Tuttolomondo A, Pinto A, Corrao S et al. Immuno-inflammatory and thrombotic/ fibrinolytic variables associated with acute ischemic stroke diagnosis. Atherosclerosis 203(2), 503-508 (2009).
58. Licata G, Tuttolomondo A, Corrao S et al. Immunoinflammatory activation during the acute phase of lacunar and non-lacunar ischemic stroke: association with time of onset and diabetic state. Int. J. Immunopathol. Pharmacol. 19(3), 639-646 (2006). (Pubitemid 44580537)
59. Tan KT, Blann AD. To stroke or not to stroke: is ICAM-1 or CRP the answer? Neurology 60(12), 1884-1885 (2003). (Pubitemid 36735999)
60. Mocco J, Choudhri TF, Mack WJ et al. Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis. Neurosurgery 48(4), 718-721; discussion 721-712 (2001).
61. Uno M, Kitazato KT, Nishi K, Itabe H, Nagahiro S. Raised plasma oxidised LDL in acute cerebral infarction. J. Neurol. Neurosurg. Psychiatry 74(3), 312-316 (2003). (Pubitemid 36259353)
62. El Husseini N, Laskowitz DT. Clinical application of blood biomarkers in cerebrovascular disease. Expert Rev. Neurother. 10(2), 189-203 (2010).
63. Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes. BMJ 303(6803), 605-609 (1991).
64. Rothwell PM, Howard SC, Power DA et al. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke 35(10), 2300-2305 (2004). (Pubitemid 39311253)
65. Ballantyne CM, Nambi V. Markers of inflammation and their clinical significance. Atheroscler. Suppl. 6(2), 21-29 (2005).
66. Tanne D, Macko RF, Lin Y, Tilley BC, Levine SR. Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke 37(7), 1798-1804 (2006). (Pubitemid 44297732)
67. Di Napoli M, Singh P. Is plasma fibrinogen useful in evaluating ischemic stroke patients?: why, how, and when. Stroke 40(5), 1549-1552 (2009).
68. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 32(1), 133-138 (2001). (Pubitemid 32063837)
69. del Zoppo GJ, Levy DE, Wasiewski WW et al. Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke 40(5), 1687-1691 (2009).
70. Gonzalez-Conejero R, Fernandez-Cadenas I, Iniesta JA et al. Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke 37(9), 2288-2293 (2006) (Pubitemid 44337171)
71. Tuttolomondo A, Di Sciacca R, Di Raimondo D et al. Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: relationship with TOAST subtype, outcome and infarct site. J. Neuroimmunol. 215(1-2), 84-89 (2009).
72. Marti-Fabregas J, Borrell M, Cocho D et al. Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA. Neurology 65(3), 366-370 (2005). (Pubitemid 41099797)
73. Haapaniemi E, Tatlisumak T. Is d-dimer helpful in evaluating stroke patients? A systematic review. Acta Neurol. Scand. 119(3), 141-150 (2009).
74. Feinberg WM, Erickson LP, Bruck D, Kittelson J. Hemostatic markers in acute ischemic stroke. Association with stroke type, severity, and outcome. Stroke 27(8), 1296-1300 (1996). (Pubitemid 26286155)
75. Welsh P, Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc. Dis. 27(3), 247-253 (2009).
76. Kang DW, Yoo SH, Chun S et al. Inflammatory and hemostatic biomarkers associated with early recurrent ischemic lesions in acute ischemic stroke. Stroke 40(5), 1653-1658 (2009).
77. Di Napoli M, Papa F. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 33(7), 1763-1771 (2002). (Pubitemid 34761057)
78. Takano K, Yamaguchi T, Kato H, Omae T. Activation of coagulation in acute cardioembolic stroke. Stroke 22(1), 12-16 (1991).
79. Audebert HJ, Pellkofer TS, Wimmer ML, Haberl RL. Progression in lacunar stroke is related to elevated acute phase parameters. Eur. Neurol. 51(3), 125-131 (2004). (Pubitemid 38608310)
80. Woodward M, Lowe GD, Campbell DJ et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 36(10), 2143-2147 (2005). (Pubitemid 41429235)
81. Bruno A, McConnell JP, Cohen SN et al. Plasma thrombosis markers following cerebral infarction in African Americans. Thromb. Res. 115(1-2), 73-77 (2005). (Pubitemid 39572758)
82. Carter AM, Catto AJ, Mansfield MW, Bamford JM, Grant PJ. Predictive variables for mortality after acute ischemic stroke. Stroke 38(6), 1873-1880 (2007). (Pubitemid 46847262)
83. Catto AJ, Carter AM, Barrett JH, Bamford J, Rice PJ, Grant PJ. von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb. Haemost. 77(6), 1104-1108 (1997). (Pubitemid 27311977)
84. Sato M, Suzuki A, Nagata K, Uchiyama S. Increased von Willebrand factor in acute stroke patients with atrial fibrillation. J. Stroke Cerebrovasc. Dis. 15(1), 1-7 (2006). (Pubitemid 43087710)
85. Ribo M, Montaner J, Molina CA et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 35(9), 2123-2127 (2004). (Pubitemid 39129572)
86. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Alvarez-Sabin J. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb. Haemost. 91(6), 1146-1151 (2004). (Pubitemid 38821271)
87. Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M et al. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J. Thromb. Haemost. 5(9), 1862-1868 (2007). (Pubitemid 47288943)
88. Montaner J, Alvarez-Sabin J, Molina CA et al. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32(12), 2762-2767 (2001). (Pubitemid 33134461)
89. Montaner J, Rovira A, Molina CA et al. Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J. Cereb. Blood Flow Metab. 23(12), 1403-1407 (2003). (Pubitemid 38018258)
90. Kelly PJ, Morrow JD, Ning M et al. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke. The Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke 39, 100-104 (2008).
91. Montaner J, Molina CA, Monasterio J et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107(4), 598-603 (2003). (Pubitemid 36176811)
92. Ning M, Furie KL, Koroshetz WJ et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology 66(10), 1550-1555 (2006). (Pubitemid 43958553)
93. Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo EH, Montaner J. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 39(4), 1121-1126 (2008). (Pubitemid 351440679)
94. Kuta AE, Baum LL. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J. Exp. Med. 164(1), 321-326 (1986). (Pubitemid 16069243)
95. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am. J. Pathol. 158(3), 1039-1051 (2001). (Pubitemid 32221796)
96. Devaraj S, O Keefe G, Jialal I. Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J. Clin. Endocrinol. Metab. 90(8), 4549-4554 (2005). (Pubitemid 41159341)
97. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J. Clin. Invest. 111(12), 1805-1812 (2003).
98. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: a critical review. J. Intern. Med. 264(4), 295-314 (2008).
99. Torzewski J, Torzewski M, Bowyer DE et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler. Thromb. Vasc. Biol. 18(9), 1386-1392 (1998). (Pubitemid 28421875)
100. Volanakis JE, Kaplan MH. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J. Immunol. 113(1), 9-17 (1974).
101. Bisoendial RJ, Kastelein JJ, Levels JH et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ. Res. 96(7), 714-716 (2005). (Pubitemid 40559509)
102. Paffen E, DeMaat MP. C-reactive protein in atherosclerosis: a causal factor? Cardiovasc. Res. 71(1), 30-39 (2006). (Pubitemid 43870060)
103. Di Napoli M, Schwaninger M, Cappelli R et al. Evaluation of C-reactive protein measurement for assessing the risk andprognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 36(6), 1316-1329 (2005). (Pubitemid 40798763)
104. Kuhlmann CR, Librizzi L, Closhen D et al. Mechanisms of C-reactive protein-induced blood-brain barrier disruption. Stroke 40(4), 1458-1466 (2009).
105. Emsley HC, Smith CJ, Gavin CM et al. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J. Neuroimmunol. 139(1-2), 93-101 (2003). (Pubitemid 36694395)
106. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch. Intern. Med. 166(19), 2073-2080 (2006). (Pubitemid 44631394)
107. Shantikumar S, Grant PJ, Catto AJ, Bamford JM, Carter AM. Elevated C-reactive protein and long-term mortality after ischaemic stroke: relationship with markers of endothelial cell and platelet activation. Stroke 40(3), 977-979 (2009).
108. den Hertog HM, van Rossum JA, van der Worp HB et al. C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death. J. Neurol. DOI: 10.1007/s00415- 009-5228-x. (2009) (Epub ahead of print).
109. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke 30(5), 981-985 (1999). (Pubitemid 29211614)
110. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 32(4), 917-924 (2001). (Pubitemid 32285161)
111. Winbeck K, Poppert H, Etgen T, Conrad B, Sander D. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 33(10), 2459-2464 (2002).
112. Montaner J, Fernandez-Cadenas I, Molina CA et al. Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 37(5), 1205-1210 (2006). (Pubitemid 43731863)
113. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107(3), 499-511 (2003). (Pubitemid 36158056)
114. Elkind MS, Luna JM, Coffey CS et al. The Levels of Inflammatory Markers in the Treatment of Stroke study (LIMITS): inflammatory biomarkers as risk predictors after lacunar stroke. Int. J. Stroke 5(2), 117-125 (2010).
115. Packard CJ, O Reilly DS, Caslake MJ et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 343(16), 1148-1155 (2000).
116. MacPhee CH, Moores KE, Boyd HF et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem. J. 338(Pt 2), 479-487 (1999).
117. White H. Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes. Curr. Opin. Cardiol. 25(4), 299-301 (2010).
118. Ballantyne CM, Hoogeveen RC, Bang H et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch. Intern. Med. 165(21), 2479-2484 (2005). (Pubitemid 41720009)
119. Oei HH, van der Meer IM, Hofman A et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111(5), 570-575 (2005). (Pubitemid 40216483)
120. Thompson A, Gao P, Orfei L et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375(9725), 1536-1544 (2010).
121. Nambi V, Hoogeveen RC, Chambless L et al. Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke 40(2), 376-381 (2009).
122. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis 27(1), 42-50 (2009).
123. Cucchiara BL, Messe SR, Sansing L et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke 40(7), 2332-2336 (2009).
124. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev. 87(3), 873-904 (2007). (Pubitemid 47086281)
125. Pervanidou P, Chrousos GP. Neuroendocrinology of post-traumatic stress disorder. Prog. Brain Res. 182, 149-160 (2010).
126. Ay H, Koroshetz WJ, Benner T et al. Neuroanatomic correlates of stroke-related myocardial injury. Neurology 66(9), 1325-1329 (2006). (Pubitemid 43739638)
127. Chamorro A, Amaro S, Vargas M et al. Catecholamines, infection, and death in acute ischemic stroke. J. Neurol. Sci. 252(1), 29-35 (2007). (Pubitemid 44909185)
128. Meyer S, Strittmatter M, Fischer C, Georg T, Schmitz B. Lateralization in autonomic dysfunction in ischemic stroke involving the insular cortex. Neuroreport 15(2), 357-361 (2004). (Pubitemid 38297365)
129. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B. Prognostic relevance of pathological sympathetic activation after acute thromboembolic stroke. Neurology 57(5), 833-838 (2001). (Pubitemid 32845504)
130. Urra X, Cervera A, Obach V, Climent N, Planas AM, Chamorro A. Monocytes are major players in the prognosis and risk of infection after acute stroke. Stroke 40(4), 1262-1268 (2009).
131. Klehmet J, Harms H, Richter M et al. Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial. Neuroscience 158(3), 1184-1193 (2009).
132. Hjemdahl P. Plasma catecholamines - analytical challenges and physiological limitations. Baillieres Clin. Endocrinol. Metab. 7(2), 307-353 (1993). (Pubitemid 23138254)
133. Giuffrida R, Bellomo M, Polizzi G, Malatino LS. Ischemia-induced changes in the immunoreactivity for endothelin and other vasoactive peptides in the brain of the Mongolian gerbil. J. Cardiovasc. Pharmacol. 20(12 Suppl.), S41-S44 (1992). (Pubitemid 23014104)
134. Nogami M, Shiga J, Takatsu A, Endo N, Ishiyama I. Immunohistochemistry of atrial natriuretic peptide in brain infarction. Histochem. J. 33(2), 87-90 (2001). (Pubitemid 32521454)
135. Nakagawa K, Yamaguchi T, Seida M et al. Plasma concentrations of brain natriuretic peptide in patients with acute ischemic stroke. Cerebrovasc. Dis. 19(3), 157-164 (2005). (Pubitemid 40754333)
136. Makikallio AM, Makikallio TH, Korpelainen JT et al. Natriuretic peptides and mortality after stroke. Stroke 36(5), 1016-1020 (2005). (Pubitemid 40629295)
137. Etgen T, Baum H, Sander K, Sander D. Cardiac troponins and N-terminal pro-brain natriuretic peptide in acute ischemic stroke do not relate to clinical prognosis. Stroke 36(2), 270-275 (2005). (Pubitemid 40170807)
138. Giannakoulas G, Hatzitolios A, Karvounis H et al. N-terminal pro-brain natriuretic peptide levels are elevated in patients with acute ischemic stroke. Angiology 56(6), 723-730 (2005). (Pubitemid 41790981)
139. Rubattu S, Stanzione R, Di Angelantonio E et al. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke 35(4), 814-818 (2004). (Pubitemid 38419783)
140. Ala-Kopsala M, Magga J, Peuhkurinen K et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin. Chem. 50(9), 1576-1588 (2004). (Pubitemid 39121226)
141. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin. Chem. 50(1), 234-236 (2004). (Pubitemid 38125732)
142. Omland T, Persson A, Ng L et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106(23), 2913-2918 (2002). (Pubitemid 35424741)
143. Omland T, de Lemos JA, Morrow DA et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am. J. Cardiol. 89(4), 463-465 (2002). (Pubitemid 34142525)
144. Gegenhuber A, Mueller T, Dieplinger B, Poelz W, Pacher R, Haltmayer M. B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure. Clin. Chim. Acta 370(1-2), 174-179 (2006). (Pubitemid 44137286)
145. Gegenhuber A, Struck J, Poelz W et al. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin. Chem. 52(5), 827-831 (2006). (Pubitemid 43673260)
146. Christ M, Thuerlimann A, Laule K et al. Long-term prognostic value of B-type natriuretic peptide in cardiac and non-cardiac causes of acute dyspnoea. Eur. J. Clin. Invest. 37(11), 834-841 (2007). (Pubitemid 350029207)
147. Katan M, Fluri F, Schuetz P et al. Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke J. Am. Coll. Cardiol. 56(13), 1045-1053 (2010).
148. Whiteley W, Rumley A, Sattar N et al. POS11 blood markers and poor outcome after acute cerebrovascular disease: a prospective cohort study. J. Neurol. Neurosurg. Psychiatry 81(11), e70 (2010).
149. Wang TJ, Gona P, Larson MG et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 355(25), 2631-2639 (2006). (Pubitemid 44969122)
150. Montaner J, Perea-Gainza M, Delgado P et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 39(8), 2280-2287 (2008).
151. Yukiiri K, Hosomi N, Naya T et al. Plasma brain natriuretic peptide as a surrogate marker for cardioembolic stroke. BMC Neurol. 8(45 (2008).
152. Chrousos GP. The hypothalamic- pituitary-adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 332(20), 1351-1362 (1995).
153. Charmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annu. Rev. Physiol. 67(259-284 (2005). (Pubitemid 40409509)
154. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 267(9), 1244-1252 (1992).
155. Volpi S, Rabadan-Diehl C, Aguilera G. Vasopressinergic regulation of the hypothalamic pituitary adrenal axis and stress adaptation. Stress 7(2), 75-83 (2004). (Pubitemid 39013697)
156. Aguilera G, Subburaju S, Young S, Chen J. The parvocellular vasopressinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stress. Prog. Brain Res. 170, 29-39 (2008). (Pubitemid 352010218)
157. Tanoue A, Ito S, Honda K et al. The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J. Clin Invest 113(2), 302-309 (2004). (Pubitemid 38544214)
158. Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol. Rev. 79(1), 1-71 (1999). (Pubitemid 29056948)
159. Johansson A, Olsson T, Carlberg B, Karlsson K, Fagerlund M. Hypercortisolism after stroke - partly cytokine-mediated? J. Neurol. Sci. 147(1), 43-47 (1997).
160. Szczudlik A, Dziedzic T, Bartus S, Slowik A, Kieltyka A. Serum interleukin-6 predicts cortisol release in acute stroke patients. J. Endocrinol. Invest. 27(1), 37-41 (2004). (Pubitemid 38324717)
161. Wilckens T, De Rijk R. Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol. Today 18(9), 418-424 (1997). (Pubitemid 27381982)
162. Besedovsky H, del Rey A, Sorkin E, Dinarello CA. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 233(4764), 652-654 (1986). (Pubitemid 16011614)
163. Fassbender K, Schmidt R, Mossner R, Daffertshofer M, Hennerici M. Pattern of activation of the hypothalamic-pituitary- adrenal axis in acute stroke. Relation to acute confusional state, extent of brain damage, and clinical outcome. Stroke 25(6), 1105-1108 (1994). (Pubitemid 24164746)
164. Olsson T, Marklund N, Gustafson Y, Nasman B. Abnormalities at different levels of the hypothalamic-pituitary- adrenocortical axis early after stroke. Stroke 23(11), 1573-1576 (1992).
165. Olsson T. Urinary free cortisol excretion shortly after ischaemic stroke. J. Intern. Med. 228(2), 177-181 (1990). (Pubitemid 20257286)
166. Christensen H, Boysen G, Johannesen HH. Serum-cortisol reflects severity and mortality in acute stroke. J. Neurol. Sci. 217(2), 175-180 (2004). (Pubitemid 38056552)
167. O Neill PA, Davies I, Fullerton KJ, Bennett D. Stress hormone and blood glucose response following acute stroke in the elderly. Stroke 22(7), 842-847 (1991).
168. Murros K, Fogelholm R, Kettunen S, Vuorela AL, Valve J. Blood glucose, glycosylated haemoglobin, and outcome of ischemic brain infarction. J. Neurol. Sci. 111(1), 59-64 (1992).
169. Slowik A, Turaj W, Pankiewicz J, Dziedzic T, Szermer P, Szczudlik A. Hypercortisolemia in acute stroke is related to the inflammatory response. J. Neurol. Sci. 196(1-2), 27-32 (2002). (Pubitemid 34311536)
170. Anne M, Juha K, Timo M et al. Neurohormonal activation in ischemic stroke: effects of acute phase disturbances on long-term mortality. Curr. Neurovasc. Res. 4(3), 170-175 (2007). (Pubitemid 47235968)
171. Neidert S, Katan M, Schuetz P et al. Anterior pituitary-axis hormones and outcome in acute ischemic stroke. J. Int. Med. DOI: 10.1111/j.1365-2796.2010. 02327.x. (2010) (Epub ahead of print).
172. Sapolsky RM, Pulsinelli WA. Glucocorticoids potentiate ischemic injury to neurons: therapeutic implications. Science 229(4720), 1397-1400 (1985). (Pubitemid 16222382)
173. Krugers HJ, Maslam S, Korf J, Joels M, Holsboer F. The corticosterone synthesis inhibitor metyrapone prevents hypoxia/ ischemia-induced loss of synaptic function in the rat hippocampus. Stroke 31(5), 1162-1172 (2000). (Pubitemid 30253541)
174. Seckl JR, Olsson T. Glucocorticoid hypersecretion and the age-impaired hippocampus: cause or effect? J. Endocrinol. 145(2), 201-211 (1995).
175. Feibel JH, Hardy PM, Campbell RG, Goldstein MN, Joynt RJ. Prognostic value of the stress response following stroke. JAMA 238(13), 1374-1376 (1977). (Pubitemid 8189214)
176. Samuels MA. The brain-heart connection. Circulation 116(1), 77-84 (2007). (Pubitemid 47016249)
177. Petraglia F, Genazzani AD, Aguzzoli L et al. Pulsatile fluctuations of plasma-gonadotropin-releasing hormone and corticotropin-releasing factor levels in healthy pregnant women. Acta Obstet. Gynecol. Scand. 73(4), 284-289 (1994). (Pubitemid 24121485)
178. Evans MJ, Livesey JH, Ellis MJ, Yandle TG. Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. Clin. Biochem. 34(2), 107-112 (2001). (Pubitemid 32322701)
179. Latendresse G, Ruiz RJ. Bioassay research methodology: measuring CRH in pregnancy. Biol. Res. Nurs. 10(1), 54-62 (2008).
180. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 26(12), 2500-2504 (2005). (Pubitemid 41676723)
181. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 26(12), 2500-2504 (2005). (Pubitemid 41676723)
182. Katan M, Fluri F, Morgenthaler NG et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann. Neurol. 66(6), 799-808 (2009).
183. Urwyler SA, Schuetz P, Fluri F et al. Prognostic value of copeptin: one-year outcome in patients with acute stroke. Stroke 41(7), 1564-1567 (2010).
184. Katan M, Nigro N, Fluri F et al. Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology DOI: 10.1212/ WNL.0b013e31820b75e6 (2011) (Epub ahead of print).
185. Darzy KH, Dixit KC, Shalet SM, Morgenthaler NG, Brabant G. Circadian secretion pattern of copeptin, the C-terminal vasopressin precursor fragment. Clin. Chem. 56(7), 1190-1191 (2010).
186. Katan M, Morgenthaler N, Widmer I et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol. Lett. 29(3), 341-346 (2008).
187. De Marchis GM, Katan M, Weck A et al. Validation of copeptin as prognostic marker in ischemic stroke. Presented at: Twentieth Meeting of the European Neurological Society. Berlin, Germany, Symposia and Free Communications, 19-23 June, 2010.
188. Vogelbaum MA, Masaryk T, Mazzone P et al. S100b as a predictor of brain metastases: brain versus cerebrovascular damage. Cancer 104(4), 817-824 (2005). (Pubitemid 41113683)
189. Staner L. Surrogate outcomes in neurology, psychiatry, and psychopharmacology. Dialogues Clin. Neurosci. 8(3), 345-352 (2006). (Pubitemid 44682751)
190. Engelter ST, Provenzale JM, Petrella JR, DeLong DM, Alberts MJ. Infarct volume on apparent diffusion coefficient maps correlates with length of stay and outcome after middle cerebral artery stroke. Cerebrovasc. Dis. 15(3), 188-191 (2003). (Pubitemid 36351204)
191. Ay H, Koroshetz WJ, Vangel M et al. Conversion of ischemic brain tissue into infarction increases with age. Stroke 36(12), 2632-2636 (2005).
192. Ay H, Arsava EM, Rosand J et al. Severity of leukoaraiosis and susceptibility to infarct growth in acute stroke. Stroke 39(5), 1409-1413 (2008).
193. Menezes NM, Ay H, Wang Zhu M et al. The real estate factor: quantifying the impact of infarct location on stroke severity. Stroke 38(1), 194-197 (2007). (Pubitemid 46035628)
194. Wu O, Koroshetz WJ, Ostergaard L et al. Predicting tissue outcome in acute human cerebral ischemia using combined diffusion- and perfusion-weighted MR imaging. Stroke 32(4), 933-942 (2001). (Pubitemid 32285163)
195. Thijs VN, Somford DM, Bammer R, Robberecht W, Moseley ME, Albers GW. Influence of arterial input function on hypoperfusion volumes measured with perfusion-weighted imaging. Stroke 35(1), 94-98 (2004). (Pubitemid 38057598)
196. Schiemanck SK, Kwakkel G, Post MW, Kappelle LJ, Prevo AJ. Predicting long-term independency in activities of daily living after middle cerebral artery stroke: does information from MRI have added predictive value compared with clinical information? Stroke 37(4), 1050-1054 (2006).
197. Schiemanck SK, Kwakkel G, Post MW, Prevo AJ. Predictive value of ischemic lesion volume assessed with magnetic resonance imaging for neurological deficits and functional outcome poststroke: a critical review of the literature. Neurorehabil. Neural Repair 20(4), 492-502 (2006). (Pubitemid 44690631)
198. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 40(5), e380-389 (2009).
199. Hlatky MA, Greenland P, Arnett DK et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119(17), 2408-2416 (2009).
200. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat. Med. 16(9), 965-980 (1997). (Pubitemid 27198985)
201. Pencina MJ, D Agostino RB Sr, D Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat. Med. 27(2), 157-172; discussion 207-112 (2008). (Pubitemid 351193639)